SYNCOM FORMULATIONS (INDIA)
|
SYNCOM FORMULATIONS (INDIA) Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2017 | Mar2016 | Mar2015 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 0.21 | 0.23 | 0.13 | 0.13 | 0.13 |
| CEPS(Rs) | 0.26 | 0.28 | 0.17 | 0.17 | 0.17 |
| DPS(Rs) | - | - | 0.02 | 0.02 | 0.02 |
| Book NAV/Share(Rs) | 2.72 | 2.52 | 1.50 | 1.39 | 1.28 |
| Tax Rate(%) | 24.47 | 24.39 | 33.65 | 35.68 | 37.60 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 8.87 | 9.12 | 8.96 | 8.98 | 10.50 |
| EBIT Margin(%) | 13.37 | 12.79 | 8.77 | 8.75 | 9.18 |
| Pre Tax Margin(%) | 11.85 | 11.92 | 8.59 | 8.68 | 9.01 |
| PAT Margin (%) | 8.95 | 9.01 | 5.70 | 5.58 | 5.62 |
| Cash Profit Margin (%) | 10.97 | 10.81 | 7.39 | 7.20 | 7.58 |
| Performance Ratios | |||||
| ROA(%) | 5.85 | 8.04 | 5.78 | 6.41 | 6.82 |
| ROE(%) | 8.48 | 11.83 | 9.32 | 9.91 | 9.99 |
| ROCE(%) | 9.68 | 13.72 | 13.28 | 14.72 | 15.55 |
| Asset Turnover(x) | 0.65 | 0.89 | 1.01 | 1.15 | 1.21 |
| Sales/Fixed Asset(x) | 2.21 | 2.28 | 2.12 | 2.28 | 2.20 |
| Working Capital/Sales(x) | 3.27 | 3.57 | 6.67 | 7.14 | 3.70 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.45 | 0.44 | 0.47 | 0.44 | 0.45 |
| Receivable days | 116.42 | 94.33 | 90.83 | 75.88 | 63.71 |
| Inventory Days | 33.13 | 24.52 | 25.15 | 25.97 | 21.92 |
| Payable days | 62.08 | 79.52 | 140.62 | 114.53 | 77.52 |
| Valuation Parameters | |||||
| PER(x) | 27.63 | 46.32 | 14.60 | 16.80 | 34.32 |
| PCE(x) | 22.54 | 38.62 | 11.26 | 13.04 | 25.45 |
| Price/Book(x) | 2.17 | 4.22 | 1.31 | 1.60 | 3.34 |
| Yield(%) | - | - | 1.02 | 0.90 | 0.47 |
| EV/Net Sales(x) | 2.81 | 4.43 | 0.86 | 0.95 | 1.93 |
| EV/Core EBITDA(x) | 18.24 | 30.42 | 8.26 | 9.00 | 16.56 |
| EV/EBIT(x) | 20.99 | 34.66 | 9.85 | 10.72 | 20.98 |
| EV/CE(x) | 1.67 | 3.16 | 0.87 | 0.96 | 2.35 |
| M Cap / Sales | 2.47 | 4.17 | 0.83 | 0.95 | 1.93 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 2.09 | 18.85 | 0.50 | 6.06 | 14.61 |
| Core EBITDA Growth(%) | 7.72 | 65.57 | 0.03 | -4.21 | 16.09 |
| EBIT Growth(%) | 6.66 | 73.35 | -0.16 | 1.95 | 10.64 |
| PAT Growth(%) | 1.42 | 87.87 | 1.72 | 6.14 | 4.72 |
| EPS Growth(%) | -6.96 | 70.10 | 1.66 | 6.16 | 4.78 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.32 | 0.27 | 0.11 | 0.05 | 0.06 |
| Current Ratio(x) | 1.61 | 1.79 | 1.47 | 1.40 | 2.28 |
| Quick Ratio(x) | 1.42 | 1.54 | 1.30 | 1.16 | 1.98 |
| Interest Cover(x) | 8.81 | 14.58 | 48.48 | 119.10 | 54.58 |
| Total Debt/Mcap(x) | 0.15 | 0.06 | 0.08 | 0.03 | 0.02 |
Compare Financial Ratios of peers of SYNCOM FORMULATIONS (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SYNCOM FORMULATIONS (INDIA) | ₹1,183.5 Cr | -3.1% | -23.6% | 96.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹365,311.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹108,623.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,134.3 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹97,408.4 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹92,794.9 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
SYNCOM FORMULATIONS (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SYNCOM FORMULATIONS (INDIA) | -3.1% |
-23.6% |
96.4% |
| SENSEX | -2.6% |
-0% |
21% |
You may also like the below Video Courses
